BET in Hematologic Tumors: Immunity, Pathogenesis, Clinical Trials and Drug Combinations

Overview

Journal Genes Dis

Date 2023 Aug 9

PMID 37554207

Authors

Tao Ma

Yan Chen

Zhi-Gang Yi

Yan-Hong Li

Jun Bai

Li-Juan Li

Lian-Sheng Zhang

Affiliations

Soon will be listed here.

Abstract

The bromodomain and extra-terminal (BET) proteins act as "readers" for lysine acetylation and facilitate the recruitment of transcriptional elongation complexes. BET protein is associated with transcriptional elongation of genes such as and , and is involved in the regulation of cell cycle and apoptosis. Meanwhile, BET inhibitors (BETi) have regulatory effects on immune checkpoints, immune cells, and cytokine expression. The role of BET proteins and BETi in a variety of tumors has been studied. This paper reviews the recent research progress of BET and BETi in hematologic tumors (mainly leukemia, lymphoma and multiple myeloma) from cellular level studies, animal studies, clinical trials, drug combination, etc. BETi has a promising future in hematologic tumors, and future research directions may focus on the combination with other drugs to improve the efficacy.

Citing Articles

PROteolysis-Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives.

Vicente A, Salvador J MedComm (2020). 2024; 5(6):e575.

PMID: 38845697 PMC: 11154823. DOI: 10.1002/mco2.575.

AI in Pharma: Transforming Drug Discovery and Strategic Management with MYC-Modulating Compounds and BET Protein Inhibitors.

Kargbo R ACS Med Chem Lett. 2024; 15(3):334-336.

PMID: 38505845 PMC: 10945536. DOI: 10.1021/acsmedchemlett.4c00057.

Small-Molecule PROTACs for Cancer Immunotherapy.

Liu Z, Zhang Y, Xiang Y, Kang X Molecules. 2022; 27(17).

PMID: 36080223 PMC: 9458232. DOI: 10.3390/molecules27175439.

References

Singh S, Dammeijer F, Hendriks R . Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018; 17(1):57. PMC: 5817726. DOI: 10.1186/s12943-018-0779-z. View

Szczepanski A, Zhao Z, Sosnowski T, Goo Y, Bartom E, Wang L . ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer. Genome Med. 2020; 12(1):63. PMC: 7362484. DOI: 10.1186/s13073-020-00760-3. View

Sun Y, Wang Y, Toubai T, Oravecz-Wilson K, Liu C, Mathewson N . BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood. 2015; 125(17):2724-8. PMC: 4408296. DOI: 10.1182/blood-2014-08-598037. View

Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry M . Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2013; 123(5):697-705. DOI: 10.1182/blood-2013-01-478420. View

Stewart H, Horne G, Bastow S, Chevassut T . BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1. Cancer Med. 2014; 2(6):826-35. PMC: 3892387. DOI: 10.1002/cam4.146. View

Andrieu G, Shafran J, Smith C, Belkina A, Casey A, Jafari N . BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response. Cancer Lett. 2019; 465:45-58. PMC: 6901183. DOI: 10.1016/j.canlet.2019.08.013. View

Lee L, Hizukuri Y, Severson P, Powell B, Zhang C, Ma Y . A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia. Haematologica. 2021; 106(4):1022-1033. PMC: 8017818. DOI: 10.3324/haematol.2020.247346. View

Ceribelli M, Kelly P, Shaffer A, Wright G, Xiao W, Yang Y . Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A. 2014; 111(31):11365-70. PMC: 4128109. DOI: 10.1073/pnas.1411701111. View

Bhadury J, Nilsson L, Muralidharan S, Green L, Li Z, Gesner E . BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci U S A. 2014; 111(26):E2721-30. PMC: 4084424. DOI: 10.1073/pnas.1406722111. View

10.

Bagratuni T, Mavrianou N, Gavalas N, Tzannis K, Arapinis C, Liontos M . JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. Eur J Cancer. 2020; 126:125-135. DOI: 10.1016/j.ejca.2019.11.017. View

11.

Booth C, Barkas N, Neo W, Boukarabila H, Soilleux E, Giotopoulos G . Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors. Cancer Cell. 2018; 33(2):274-291.e8. DOI: 10.1016/j.ccell.2018.01.006. View

12.

Marmorstein R, Zhou M . Writers and readers of histone acetylation: structure, mechanism, and inhibition. Cold Spring Harb Perspect Biol. 2014; 6(7):a018762. PMC: 4067988. DOI: 10.1101/cshperspect.a018762. View

13.

Erkes D, Field C, Capparelli C, Tiago M, Purwin T, Chervoneva I . The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner. Pigment Cell Melanoma Res. 2019; 32(5):687-696. PMC: 6697571. DOI: 10.1111/pcmr.12788. View

14.

Gabizon R, London N . A Fast and Clean BTK Inhibitor. J Med Chem. 2020; 63(10):5100-5101. PMC: 7304894. DOI: 10.1021/acs.jmedchem.0c00597. View

15.

Latif A, Newcombe A, Li S, Gilroy K, Robertson N, Lei X . BRD4-mediated repression of p53 is a target for combination therapy in AML. Nat Commun. 2021; 12(1):241. PMC: 7801601. DOI: 10.1038/s41467-020-20378-8. View

16.

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

17.

Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E . Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2017; 61(2):462-481. PMC: 5788414. DOI: 10.1021/acs.jmedchem.6b01816. View

18.

Ryan C, Davids M . BCL-2 Inhibitors, Present and Future. Cancer J. 2019; 25(6):401-409. DOI: 10.1097/PPO.0000000000000408. View

19.

Delmore J, Issa G, Lemieux M, Rahl P, Shi J, Jacobs H . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146(6):904-17. PMC: 3187920. DOI: 10.1016/j.cell.2011.08.017. View

20.

Duan Y, Guan Y, Qin W, Zhai X, Yu B, Liu H . Targeting Brd4 for cancer therapy: inhibitors and degraders. Medchemcomm. 2018; 9(11):1779-1802. PMC: 6238758. DOI: 10.1039/c8md00198g. View